Skip to main content

Advertisement

SpringerLink
Log in

Evaluation of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Colorectal Origin in the Era of Value-Based Medicine

  • Colorectal Cancer
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Peritoneal spread from colorectal cancer is second only to the liver as a site for metastasis. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) is a well-established treatment option for patients with peritoneal carcinomatosis (PC) of colorectal origin. However, due to concerns regarding both its clinical benefit and high cost, its universal adoption as the standard of care for patients with limited peritoneal dissemination has been slow. The purpose of this review was to clarify the clinical utility and cost effectiveness of CRS-HIPEC in the treatment of colorectal PC using the framework of value-based medicine, which attempts to combine both benefit and cost into a single quantifiable metric. Our comprehensive review of the clinical outcomes and cost effectiveness of CRS-HIPEC demonstrate that it is a highly valuable oncologic therapy and a good use of healthcare resources.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Segelman J, Granath F, Holm T, Machado M, Mahteme H, Martling A. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2012;99:699–705.

    Article  CAS  PubMed  Google Scholar 

  2. Jayne DG, Fook S, Loi C, Seow-Choen F. Peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2002;89:1545–50.

    Article  CAS  PubMed  Google Scholar 

  3. Esquivel J, Sticca R, Sugarbaker P, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology. Ann Surg Oncol. 2007;14:128–33.

    Article  CAS  PubMed  Google Scholar 

  4. Dube P, Sideris L, Law C, et al. Guidelines on the use of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal surface malignancy arising from colorectal or appendiceal neoplasms. Curr Oncol. 2015;22:e100–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Chua TC, Yan TD, Saxena A, Morris DL. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure? A systematic review of morbidity and mortality. Ann Surg. 2009;249:900–7.

    Article  PubMed  Google Scholar 

  6. Elias D, Gilly F, Boutite F, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010;28:63–8.

    Article  PubMed  Google Scholar 

  7. Elias D, Lefevre JH, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009;27:681–5.

    Article  PubMed  Google Scholar 

  8. Chua TC, Esquivel J, Pelz JO, Morris DL. Summary of current therapeutic options for peritoneal metastases from colorectal cancer. J Surg Oncol. 2013;107:566–73.

    Article  PubMed  Google Scholar 

  9. Porter ME. What is value in health care? N Engl J Med. 2010;363:2477–81.

    Article  CAS  PubMed  Google Scholar 

  10. Dawson LE, Russell AH, Tong D, Wisbeck WM. Adenocarcinoma of the sigmoid colon: sites of initial dissemination and clinical patterns of recurrence following surgery alone. J Surg Oncol. 1983;22:95–9.

    Article  CAS  PubMed  Google Scholar 

  11. Chu DZ, Lang NP, Thompson C, Osteen PK, Westbrook KC. Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer. 1989;63:364–7.

    Article  CAS  PubMed  Google Scholar 

  12. Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000;88:358–63.

    Article  CAS  PubMed  Google Scholar 

  13. Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21:3737–43.

    Article  PubMed  Google Scholar 

  14. Franko J, Shi Q, Goldman CD, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol. 2012;30:263–7.

    Article  PubMed  Google Scholar 

  15. Verwaal VJ, van Ruth S, Witkamp A, Boot H, van Slooten G, Zoetmulder FA. Long-term survival of peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol. 2005;12:65–71.

    Article  PubMed  Google Scholar 

  16. Levine EA, Stewart JH 4th, Shen P, Russel GB, Loggie BL, Votanopoulous KI. Intraperitoneal chemotherapy for peritoneal surface malignancy: experience with 1,000 patients. J Am Coll Surg. 2014;218:573–85.

    Article  PubMed  Google Scholar 

  17. Kusamura S, Baratti D, Deraco M. Multidimensional analysis of the learning curve for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal surface malgnancies. Ann Surg. 2012;255:348–56.

    Article  PubMed  Google Scholar 

  18. Kuijpers AM, Mirck B, Aalbers AG, et al. Cytoreduction and HIPEC in the Netherlands: a nationwide long-term outcome following the Dutch protocol. Ann Surg Oncol. 2013;20:4224–30.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Elias D, Gilly F, Boutite F, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010;28:63–8.

    Article  PubMed  Google Scholar 

  20. Elias D, Lefevre JH, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009;27:681–5.

    Article  PubMed  Google Scholar 

  21. Chua TC, Esquivel J, Pelz JO, Morris DL. Summary of current therapeutic options for peritoneal metastases from colorectal cancer. J Surg Oncol. 2013;107:566–73.

    Article  PubMed  Google Scholar 

  22. Jafari MD, Halabi WJ, Stamos MJ, Nguyen VQ, Carmichael JC, Mills SD, Pigazzi A. Surgical outcomes of hyperthermic intraperitoneal chemotherapy: analsysi of the American College of Surgeons national surgical quality improvement program. JAMA Surg. 2014;149:170–5.

    Article  PubMed  Google Scholar 

  23. Chua TC, Yan TD, Saxena A, Morris DL. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure? A systematic review of morbidity and mortality. Ann Surg. 2009;249:900–7.

    Article  PubMed  Google Scholar 

  24. Yan TD, Links M, Fransi S, Jacques T, Black D, Saunders V, et al. Learning curve for cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal surface malignancy: a journey to becoming a Nationally Funded Peritonectomy Center. Ann Surg Oncol. 2007;14:2270–80.

    Article  PubMed  Google Scholar 

  25. Winter JM, Cameron JL, Campbell KA, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. J Gastrointest Surg. 2006;10:1199–210.

    Article  PubMed  Google Scholar 

  26. McQuellon RP, Loggie BW, Fleming RA, Russel GB, Lehman AB, Rambo TD. Quality of life after intraperitoneal hyperthermic chemotherapy (IPHC) for peritoneal carcinomatosis. Eur J Surg Oncol. 2001;27:65–73.

    Article  CAS  PubMed  Google Scholar 

  27. McQuellon RP, Loggie BW, Lehman AB, Russel GB, Fleming RA, Shen P, et al. Long-term survivorship and quality of life after cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol. 2003;10:155–62.

    Article  PubMed  Google Scholar 

  28. Passot G, Bakrin N, Roux AS, Vandoyer D, Gilly FN, Glehen O, et al. Quality of life after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy: a prospective study of 216 patients. Eur J Surg Oncol. 2014;40:529–35.

    Article  CAS  PubMed  Google Scholar 

  29. Piso P, Glockzin G, von Breitenbuch P, Popp FC, Dahlke MH, Schlitt HJ, et al. Quality of life after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies. J Surg Oncol. 2009;100:317–20.

    Article  PubMed  Google Scholar 

  30. Tsilimparis N, Bockelmann C, Raue W, Menenakos C, Perez S, Rau B, et al. Quality of life in patients after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is it worth the risk? Ann Surg Oncol. 2013;20:226–32.

    Article  PubMed  Google Scholar 

  31. Chia CS, Tan WJ, Wong JF, et al. Quality of life in patients with peritoneal surface malignancies after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol. 2014;40:909–16.

    Article  CAS  PubMed  Google Scholar 

  32. Baratti D, Scivales A, Balestra MR, et al. Cost analysis of the combined procedure of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Surg Oncol. 2010;36:463–9.

    Article  CAS  PubMed  Google Scholar 

  33. Bagnoli PF, Cananzi FC, Brocchi A, et al. Peritonectomy and hyperthermic intraperitoneal chemotherapy: cost analysis and sustainability. Eur J Surg Oncol. 2015;41:386–91.

    Article  PubMed  Google Scholar 

  34. Tentes AA, Pallas N, Korakianitis O, et al. The cost of cytoreductive surgery and perioperative intraperitoneal chemotherapy in the treatment of peritoneal malignancy in one Greek institute. J BUON. 2012;17:776–80.

    CAS  PubMed  Google Scholar 

  35. Chua TC, Martin S, Saxena A, et al. Evaluation of the cost-effectiveness of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (peritonectomy) at the St George Hospital peritoneal surface malignancy program. Ann Surg. 2010;251:323–9.

    Article  PubMed  Google Scholar 

  36. Koppe MJ, Boerman OC, Oyen WJ, Bleichrodt RP. Peritoneal carcinomaotiss of colorectal origin: incidence and current treatment strategies. Ann Surg. 2006;243: 212–22.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol. 2005;23:3502–08.

    Article  CAS  PubMed  Google Scholar 

  38. National Health and Medical Research Council. How to compare the costs and benefits: evaluation of the economic evidence. Canberra: Commonwealth of Australia; 2001.

    Google Scholar 

  39. Ananda S, Kosmider S, Tran B, et al. The rapidly escalating cost of treating colorectal cancer in Australia. Asia Pac J Clin Oncol. 2015; doi:10.1111/ajco.12350

    Google Scholar 

  40. Bonastre J, Chevalier J, Elias D, et al. Cost-effectiveness of intraperitoneal chemohyperthermia in the treatment of peritoneal carcinomatosis from colorectal cancer. Value Health. 2008;11:347–353.

    Article  PubMed  Google Scholar 

  41. Wilson J, Connock M, Song F, Yao G, Fry-Smith A, Raftery J, et al. Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation. Health Technol Assess. 2005;9:1–142.

    CAS  PubMed  Google Scholar 

  42. Elkin EB, Weinstein MC, Winer EP, Kuntz KM, Schnitt SJ, Weeks JC. HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol. 2004;22:854–63.

    Article  PubMed  Google Scholar 

Download references

Disclosures

Dr. Vanounou receives a consulting fee from Roche, while Dr. Garfinkle has no relevant disclosures.

Author information

Authors and Affiliations

  1. Division of General Surgery, Sir Mortimer B. Davis Jewish General Hospital, Montreal, QC, Canada

    Tsafrir Vanounou & Richard Garfinkle

Authors
  1. Tsafrir Vanounou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard Garfinkle
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Richard Garfinkle.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vanounou, T., Garfinkle, R. Evaluation of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Colorectal Origin in the Era of Value-Based Medicine. Ann Surg Oncol 23, 2556–2561 (2016). https://doi.org/10.1245/s10434-016-5096-4

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-016-5096-4

Keywords

Search

Navigation